Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + morphine + ketamine
- Development stage
- Phase 4
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Paracetamol + morphine + ketamine is a multimodal analgesic combination therapy being evaluated for the management of pain during vaso-occlusive crises (VOC) in adult patients with sickle cell disease (SCD). The combination utilizes three distinct mechanisms of pain relief: paracetamol (acetaminophen) acts primarily through central analgesic pathways, morphine is a strong opioid agonist targeting mu-opioid receptors, and ketamine is an NMDA receptor antagonist that acts as a co-analgesic to prevent opioid-induced hyperalgesia and reduce overall opioid consumption. This combination is being studied in the PAMAVOC adaptive platform trial sponsored by Assistance Publique - Hôpitaux de Paris (AP-HP) to optimize pain management protocols and minimize opioid-related adverse effects.
- Other names
- acetaminophen + morphine + ketamineketamine + morphine + acetaminophenketamine + morphine + paracetamolmorphine + acetaminophen + ketaminemorphine + paracetamol + ketamineparacetamol + morphine + ketamine
02
Targets
MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on paracetamol + morphine + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + morphine + ketamine.